Methods of detecting hypoxia-associate peptides
OwnerYe Huinventor
Life of this patent
Estimating the term…
Abstract
In certain embodiments, the present invention provides a method of detecting hypoxia status in a tumor cell by detecting a level of hydroxyprolyl BK (Hyp-BK) peptides in a patient sample, and detecting a level of bradykinin (BK) peptides the patient sample, wherein a change in the Hyp-BK/BK ratio as compared to the Hyp-BK/BK ratio in a comparable normal cell is a marker for tumor hypoxia.
Claims16
A method of detecting hypoxia status in a tumor cell comprising
- (a) detecting a level of hydroxyprolyl BK (Hyp-BK) peptides in a patient sample, and
- (b) detecting a level of bradykinin (BK) peptides the patient sample,
- wherein an increased Hyp-BK/BK ratio as compared to the Hyp-BK/BK ratio in a comparable normal cell is a marker for tumor hypoxia.
A method of detecting hypoxia status in a tumor cell comprising
- (a) detecting a level of hydroxyprolyl BK (Hyp-BK) in a patient sample, and
- (b) detecting a level of bradykinin (BK) the patient sample,
- wherein BK and Hyp-BK peptides from the patient sample are subjected to nanopore-based fractionation and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
A method of treating a hyperproliferative disorder in a patient in need thereof comprising administering to a patient identified as having a low or high plasma hydroxyprolyl BK (Hyp-BK)/protein bradykinin (BK) ratio as compared to a normal or control value a pharmaceutical composition comprising a chemotherapeutic agent.
Dependencies are inferred from the claim text.